Browse more peptide research, methods and limitations.
Fatty acid conjugation of AMPs enhances membrane interaction, antimicrobial potency, proteolytic stability, and in vivo persistence through albumin binding, with applications expanding to antibiofilm and drug delivery.
Helmy, Naiera M; Davani-Davari, Dorna; Parang, Keykavous ·
AUD risk reduction vs DPP-4i: tirzepatide HR 0.47 (0.29-0.75); semaglutide HR 0.68 (0.52-0.89); liraglutide and dulaglutide: NS. Tirzepatide vs liraglutide head-to-head: HR 0.47 (0.24-0.92).
Henney, Alex E; Riley, David R; Heague, Megan; Roberts, Carl A; Hydes, Theresa J; Anson, Matthew; Hughes, David M; Alam, Uazman; Cuthbertson, Daniel J ·
Cancer incidence HR: metformin 0.96; GLP-1 RA 0.86; dual 0.61. All-cause mortality HR: metformin 0.78; GLP-1 RA 0.61; dual 0.33. Dual therapy effects strongest in younger, male, obese patients.
Henney, Alex E; Heague, Megan; Riley, David R; Hydes, Theresa J; Anson, Matthew; Alam, Uazman; Cuthbertson, Daniel J ·
GLP-1 users: no increased SSI (OR 0.9, p=0.79), PJI (OR 0.7, p=0.40), or 1-year complications. Shorter LOS ≥3 days (OR 0.6, p<0.001). 1,018 GLP-1 users vs 4,493 matched controls from 26,271 UKA patients.
Heo, Kevin Y; Worden, Jacob A; Arellano, Emilio; Chang, Jerry; Ross, Bailey J; Karzon, Anthony L; Premkumar, Ajay; Wilson, Jacob M ·
GLP-1 RA vs metformin: cardiomyopathy risk 0.31% vs 0.94%; HR 0.43 (0.24-0.76, p<0.001); consistent across high-risk subgroups; up to 18.5 years follow-up.
Hernández-Pérez, Jesús Gibran; Abdelgadir, Omer; Hussain, Maryam R; Almandoz, Jaime P; Barcenas, Carlos H; Shah, Amil; Cowell, Lindsay G; Messiah, Sarah E; Lopez, David S ·
Fremanezumab vs placebo: migraine days -2.5 vs -1.4 (difference 1.1, p=0.02); moderate-severe headache days -2.6 vs -1.5 (p=0.02); ≥50% responder: 47.2% vs 27.0% (p=0.002). Injection-site erythema: 9.8% vs 5.4%.
Hershey, Andrew D; Szperka, Christina L; Barbanti, Piero; Pozo-Rosich, Patricia; Bittigau, Petra; Barash, Steve; Bryson, Juline; Kessler, Yoel; Carmeli Schwartz, Yael; Ramirez Campos, Verena; Ning, Xiaoping ·
GLP-1 RAs in youth: BMI -1.7 (p=0.02), ALT -3.0 (p=0.01). No significant changes in HDL, LDL, or HbA1c. 6 RCTs included (4 exenatide, 1 semaglutide, 1 liraglutide).
Hertzer, Lauren A; Siegel, Robert M; Kharofa, Roohi Y; Stackpole, Kristin M; Mahabee-Gittens, E Melinda ·
SGLT2i and GLP-1 RAs most consistently reduce EAT thickness, suppress inflammation, enhance insulin sensitivity, and promote adipocyte browning/oxidative metabolism, shifting EAT toward a less pathological phenotype.
Heuboeck, Elisabeth; Bhogal, Charnkamal Singh; Mandl, Markus ·
Week 48 weight loss: bimagrumab 30 -9.3 kg; semaglutide 2.4 -14.2 kg; combination -17.8 kg; placebo -3.3 kg (all p<0.001 vs placebo). Improvements continued through week 72. Safety consistent with known profiles.
Heymsfield, Steven B; Aronne, Louis J; Montgomery, Penelope; Klickstein, Lloyd B; Coleman, Laura A; Dole, Kiran; Mindeholm, Linda; Spruill, Susan; Li, Xingyuan; Attie, Kenneth M ·
Arenin: glucose uptake increased from 23.97% to 51.38% in IR hepatocytes at 250 μg/mL; time-dependent ROS reduction (lowest 15.78% at 15.62 μg/mL at 24h); concentration-dependent NO immunomodulation in macrophages.
Hidalgo-Vázquez, Enrique; Antunes-Ricardo, Marilena; Hernández-Pérez, Jesús; Benavides, Jorge ·
15-40% of incretin-induced weight loss is lean mass; pipeline solutions include SARMs, myostatin/TGF-β inhibitors, and siRNA; current limitations: parenteral delivery, short trials, sparse functional outcomes, FDA focus on total weight not composition.
Hierholzer, Justin; Benson, Harrison; Ewida, Heba A; Ahmed, Mahmoud Salama ·
No significant difference in SGLT2i/GLP-1 RA prescribing: PLWH 30.0% vs controls 28.3% (p=0.86). Only ~33% with established CVD received these drugs (p=0.63). PLWH had more self-care difficulties (p=0.038).
Hilgefort, L; Potthoff, A; Nambiar, S; Schlottmann, R; Kaup, B; Ebigbo, A; Schmidt, W E; Nonseid-Jansen, H; Jansen, W A; Skaletz-Rorowski, A; Quast, D R ·
GLP-1 RA vs non-use: respiratory complications 0.39% vs 0.50% (OR 0.79, p=0.41); severe respiratory 0.11% vs 0.077% (OR 1.45, p=0.52). Trends in new users (OR 1.43, NS) and severe diabetes (OR 1.28, NS).
Hisada, Hiroyuki; Ikeuchi, Kazuhiko; Tsuji, Yosuke; Yamamichi, Nobutake; Kakushima, Naomi; Okushin, Kazuya; Yakabi, Seiichi; Takeuchi, Chihiro; Ohki, Daisuke; Mizutani, Hiroya; Miura, Yuko; Kubota, Dai; Tsutsumi, Takeya; Fujishiro, Mitsuhiro ·
Weight loss in MC4R KO mice: semaglutide 19.7%, tirzepatide 31.6%, retatrutide 24.1%. All improved insulin, HOMA-IR, cholesterol, AST/ALT, and suppressed FA synthesis genes. Only tirzepatide reduced RQ. No effect on inflammation genes.
Hitaka, Kosuke; Sugawara, Takumi; Matsumoto, Mitsuharu; Nio, Yasunori ·
Glucagon/GLP-1 from alpha cells destabilize beta-cell microtubules via GcgR/GLP-1R, enabling insulin granule release. Proximity to alpha cells enhances microtubule dynamics and insulin secretion. HFD attenuates this inter-cellular signaling.
Ho, Kung-Hsien; Barmaver, Syed N; Gibson, Shannon E; Hu, Ruiying; Yagan, Mahircan; Ahmed, Hamida K; Balamurugan, Appakalai N; Jacobson, David A; Kaverina, Irina; Gu, Guoqiang ·
Over ≥12 months: 3% discontinuation due to AEs (vs 23% total discontinuation); AE rate >70% reported but stable/non-serious; no emergent safety signals; consistent across erenumab, fremanezumab, galcanezumab, eptinezumab.
Hoehne, Carolin Luisa; Overeem, Lucas Hendrik; Sanchez-Del-Rio, Margarita; Deligianni, Christiana; Gil-Gouveia, Raquel; Versijpt, Jan; Amin, Faisal Mohammad; Lampl, Christian; Ryliskiene, Kristina; Tronvik, Erling; Coppola, Gianluca; Holland, Philip R; MaassenVanDenBrink, Antoinette; Martelletti, Paolo; Reuter, Uwe ·
Multi-society guidance: patients without risk factors may continue GLP-1 RA for procedures under conscious sedation. Case-by-case risk assessment and shared decision-making recommended. Conscious sedation may not be necessary in most scenarios.
Holder, Eric K; Ni, Amelia; Levi, David ·
Preoperative GLP-1 use: %TWL at 12 months 20.7% vs 22.0% non-users (p=0.19). Diabetes active-comparator: 21.5% vs 23.1% (p=0.39). Pre-op BMI higher for GLP-1 users 12 months pre-op (47.0 vs 44.4) but similar at surgery (45.9 vs 46.1).
Holler, Emma; Samuels, Jason M; Stefanidis, Dimitrios; Yuce, Tarik K ·
In females, exercise maintained fasting and postprandial LEAP2 during weight maintenance after LCD, while liraglutide did not. In males, LEAP2 decreased with LCD and remained low regardless of intervention. Sex-specific LEAP2 regulation.
Holt, Joachim; Holm, Stephanie K; Sandsdal, Rasmus M; Jensen, Simon B K; Juhl, Christian R; Noer, Mikkel H; Afshar-Bahadori, Yasmin; Blond, Martin B; Gerds, Thomas A; Stallknecht, Bente M; Madsbad, Sten; Holst, Jens J; Holst, Birgitte; Hartmann, Bolette; Byberg, Sarah; Torekov, Signe S ·
Exercise increased late-phase postprandial GLP-1 by 37% within-group (p<0.001) and 25% vs usual activity (p=0.02). Liraglutide did not change endogenous GLP-1 response. Diet-induced weight loss did not alter GLP-1 (3%, NS).
Holt, Joachim; Sandsdal, Rasmus Michael; Byberg, Sarah; Janus, Charlotte; Juhl, Christian Rimer; Jørgensen, Julie Rehné; Hartmann, Bolette; Stallknecht, Bente; Holst, Jens Juul; Madsbad, Sten; Jensen, Simon Birk Kjær; Torekov, Signe Sørensen ·
Tirzepatide vs non-GIP GLP-1 RA (102,590 per cohort): DR HR 0.60 (0.54-0.65); DME HR 0.63 (0.52-0.74); VH/RD HR 0.36 (0.23-0.55); vision-saving interventions HR 0.44 (0.32-0.60); NAION HR 0.31 (0.15-0.64).
Hong, Alexander T; Lin, Forest; Keenan, Jeremy D; Stewart, Jay M ·
Tirzepatide vs GLP-1 RA: POAG RR 0.50 (0.34-0.74); OHTN RR 0.59 (0.40-0.88); glaucoma treatment RR 0.54 (0.45-0.64). Consistent with metformin/insulin subgroups and individual GLP-1 RA comparisons. 41,849 matched pairs.
Hong, Alexander T; Lin, Forest; Baxter, Sally; Weinreb, Robert N ·
Nanobody-LOOP2 conjugates recruited vaccine-induced anti-HBsAg antibodies to EGFR+ cancer cells, evoking ADCP and CDC. PEG spacer minimally affected ADCP but significantly impacted CDC. Proof-of-concept for vaccine-based ARM therapeutics.
Hong, Haofei; Zhang, Zijiang; Wang, Zheng; Zhang, Zongqin; Zhang, Linpei; Wu, Zhimeng ·
After tirzepatide withdrawal, weight regain ≥75% in most patients within 1 year. Cardiometabolic reversal proportional to regain: waist (+0.8 to +14.7 cm), SBP (+6.8 to +10.4 mmHg), HbA1c (+0.14 to +0.35%), fasting insulin (-4% to +46%) across <25% to ≥75% regain categories.
Horn, Deborah B; Linetzky, Bruno; Davies, Melanie J; Laffin, Luke J; Wang, Hui; Murphy, Madhumita A; Zimner-Rapuch, Sarah; Lau, Eva; Arad, Avigdor D; Lee, Clare J ·
Orforglipron 36 mg: -7.9% body weight, -1.4% HbA1c at 40 weeks; 66% achieved ≥5% weight loss; most common AEs: nausea, diarrhea, vomiting; oral non-peptide GLP-1 RA; phase 3 ATTAIN-2 trial.
Horn, Deborah B; Ryan, Donna H; Kis, Sanja Giljanovic; Alves, Breno; Mu, Yiming; Kim, Sin Gon; Aberle, Jens; Bain, Stephen C; Allen, Sheryl; Sarker, Elizabeth; Wu, Qiwei; Stefanski, Adam; Jouravskaya, Irina ·
GLP-1 and GIP/GLP-1 agonists may improve CF pulmonary function through glycemic control, anti-inflammatory effects, weight management, and potential direct airway effects, warranting CF-specific clinical trials.
Horvit, Andrew; Kaput, Katie; Neece, Amber; Abramowitz, Jessica; Abreu, Marconi; Ratti, Gregory A; Finklea, James D; Jain, Raksha; Mirfakhraee, Sasan ·
Liraglutide modulated zinc release and improved mitochondrial bioenergetics in insulin-resistant hepatocytes, revealing zinc-mitochondria crosstalk as a novel GLP-1 drug mechanism.
Hosseinpourshirazi, Fatemeh; Mendes, Umur D; Aksoy, Zeynep B; Aydos, Dunya; Sözer, Merve; Aljaser, Lubne; Gundogdu, Manolya; Sık, Suatnur; Tuncay, Erkan; Turan, Belma; Olgar, Yusuf ·
Fremanezumab reduced the frequency and duration of prolonged sporadic hemiplegic migraine attacks in a case series, with no safety concerns despite theoretical vascular considerations.
Hotz, Julian Frederic; Kaindl, Lisa; Krebs, Stefan; Vigl, Marion; Ferrari, Julia; Neumann, Christian; Han, Robert; Ritscher, Lavinia; Sykora, Marek; Gallmetzer, Paolo ·
RVG29-functionalized PEG-PLGA NPs crossed BBB via nicotinic acetylcholine receptor binding, delivered α-lipoic acid to brain, and attenuated seizure-induced oxidative brain damage in epilepsy model.
Hou, Jianxun; Hao, Lei; Du, Wei; Su, Qiuyu; Xiong, Qijiang; Zhao, Wang; Yang, Zhao ·
GLP-1 RAs associated with lower risk of infections compared to SGLT2i in T2D patients with advanced CKD, particularly urinary tract and genital infections.
Hsiao, Ching Chung; Chen, Jia-Jin; Huang, Shu-Chun; Yen, Chieh-Li; Ho, Wen-Yu; Fang, Yu-Wei; Chen, Mon-Ting; Yang, Jeng How; Tsai, Ming-Hsien ·
GLP-1 RA use in T2D patients with prior MALEs was associated with reduced subsequent cardiovascular events, limb-related complications, and mortality.
Hsiao, Fu-Chih; Hsu, Tzyy-Jer; Hsieh, Yu-Jui; Tung, Ying-Chang; Chen, Dong-Yi; Lin, Chia-Pin; Chen, Shao-Wei; Chu, Pao-Hsien ·
GLP-1 RA therapy associated with improved AVF outcomes: reduced thrombosis, stenosis, and revision rates in hemodialysis patients with ESKD.
Hsu, Joshua; Ho, Bryan; Sayed, Rahman; Patel, Nathan T P; Dardik, Alan ·
Melittin binds NRP-1 directly (confirmed by docking and SPR), selectively suppresses EndMT via TGF-β/Smad and MAPK inhibition, dose-dependently reduces bleomycin PF and improves survival. M-pLNPs sustain lung levels >24h enabling lower dosing.
Hu, Ming; Wan, Yingying; Chen, Jiakang; Zhang, Chengwei; Li, Shuze; Shan, Bingbing; Wu, Ling; Yu, Xiang ·
L. lactis/HI: optimized freeze-drying (6% sorbitol), reduced ETEC colonization and LPS, restored tight junction genes, downregulated TNF-α/IL-1β/IL-6, upregulated IL-10 in ETEC-infected mouse intestine.
Hu, Mingyang; Bi, Chongpeng; Li, Yuwen; Xue, Yutong; Cha, Sina; Zhao, Lu; Xue, Chenyu; Dong, Na ·
CGRP+ fiber remodeling post-SCI regulates macrophage polarization time-dependently via CLR/RAMP1 and cAMP/PKA/MAPK. Cross-regulation with NF-κB/STAT3 and synergy with other neuropeptides shapes the neuroimmune microenvironment.
Hu, Rong; Lou, Yuchen; Wang, Lanlan; He, Wenjie; Ma, Xinyuan; Li, Xinyun; Yue, Zenghui ·
GLP-1R activation → HF: OR 0.50 (IVW). Primary mediator: BMI (67.2%), T2D (45%). After BMI adjustment: OR 0.59 (significant). After T2D adjustment: OR 0.51 (significant). Residual direct cardioprotection confirmed.
Hu, Yiqing; Zhao, Yongchao; Dai, Neng; Zhou, You; Yao, Yunqian; Li, Ziang; Cai, Wufeng; Xiong, Weidong; Song, Shuai; Deng, Xin; Yin, Jiasheng; Zhao, Xin; Weng, Xinyu; Li, Chenguang; Sun, Aijun; Qian, Juying; Lu, Hao; Ge, Junbo ·
Seven enzymes produced distinct porcine collagen peptide profiles. Alkaline protease: smallest MW, best radical scavenging. Two stable peptides (GI*PGPAGAAGATGAR and GF*PGS*PGNVGPAGK) identified as universal traceability markers.
Hu, Yu-Ting; Tu, Zong-Cai; Liu, Guang-Xian; Peng, Chun-Yan; Zhang, Peng; Xie, Wen-Ming; Yang, Le-Ying; Chen, Yu; Hu, Zi-Zi; Sha, Xiao-Mei ·
T1D: elevated basal GH (p=0.002), exaggerated GH response to hypoglycemia (p=0.002). T2D: higher ACTH (p=0.024) and cortisol (p=0.043) during hypoglycemia, lower testosterone, higher estradiol vs T1D (p<0.001).
Hu, Yun; Yan, Reng-Na; Cai, Ting-Ting; Zhu, Xiao-Wei; Ma, Jian-Hua; Ding, Bo ·
SGLT2i vs GLP-1 RA (294,664 per cohort): RCC HR 0.85 (0.79-0.92); UCC HR 0.85 (0.78-0.92); mean follow-up 44.2 months; consistent across demographic and comorbidity subgroups.
Huang, Chien-Wei; Lai, Edward Chia-Cheng; Wu, Vin-Cent; Hsieh, Miyuki Hsing-Chun; Li, Chia-Jung; Chang, Renin; Chen, Jin-Shuen; Tsai, Yau-Sheng; Sung, Junne-Ming ·
GLP-1 RAs may restore retinal proteostasis by fine-tuning PERK/IRE1α UPR pathways, alleviating ER stress-driven retinal vascular dysfunction, neuroinflammation, and neuronal apoptosis in diabetic retinopathy.
Huang, Hanwen; Wang, Ya'nuo; Gao, Shuang; Li, Na; Zhong, Yisheng; Shen, Xi ·
Genetically proxied GLP-1 RA use was associated with increased acute pancreatitis risk but not other gastrointestinal adverse events in Mendelian randomization analysis.
Huang, Haozhang; Liu, Jin; Lu, Xiaozhao; Tan, Ning; Liu, Yong ·
CHCH_KRVL_3: MIC 8 μM vs MDR A. baumannii, SI >10, specific PE/PG binding → membrane permeabilization → sustained ROS. Superior antibiofilm vs polymyxin B on PVC tubes. Generalizable "natural module + CHCH scaffold" AI platform.
Huang, Heyang; Sheng, Lina; Ye, Yongli; Sun, Jiadi; Ji, Jian; Zhao, Hongjing; Sun, Xiulan ·
P3-3R-8I: dual membrane penetration + DNA binding mechanism; kills MRSA and E. coli rapidly; heals MRSA-infected wounds in rats; clears lung/spleen in MRSA systemic sepsis. Precisely engineered via Arg/Ile mutations targeting bacterial membranes.
Huang, Jiaqi; Liu, Bohao; Zhu, Xingzhuo; Qiao, Deqian; Chen, Sizhe; Zeng, Xiaoyan; Yang, Qingqing; Wei, Zihuan; Huang, Yinjuan; Wang, Jizhao; Zhang, Guangjian; Gong, Qiuyu ·
Few-shot AI pipeline: scanned tens of billions of peptides; discovered AMPs vs A. baumannii and C. albicans; low toxicity; no resistance; EME7(7) controlled pneumonia in mice without kidney injury (unlike polymyxin B).
Huang, Junjie; Zhang, Wentao; Wang, Aowen; Jiang, Yunzhi; Lai, Yuxian; Xu, Yanchao; Wang, Cong; Zhao, Junbo; Zhang, Peng; Ji, Jian ·
Dibifree: significant HbA1c, FPG, PPG reduction vs placebo in crossover RCT; mechanisms: enhanced GLP-1 secretion, DPP-4/α-glucosidase inhibition, reduced AGE, suppressed adipogenesis, M2 macrophage promotion; transcriptomic reversal of diabetic signatures.
Huang, Tzu-Yi; Dai, Niann-Tzyy; Liao, Hsiu-Jung; Doan, Ly Hien; Cheng, Tai-Shan; Hsieh, Wen-Yu; Lin, I-Hsuan; Huang, Yu-Tang; Liaw, Chia-Ching; Liu, Hsiao-Sheng; Cheng, Wei-Ming; Su, Chun-Li; Yang, Ching-Wei; Lai, Jin-Mei; Tuan, Mei-Nan; Liu, Hui-Kang; Huang, Chi-Ying F ·
A peptide drug targeting SASH1-PKM2 interaction modulated astrocyte reactivity, reduced glial scar formation, and promoted neural recovery in traumatic brain injury models.
Huang, Xinyuan; Kong, Roujia; Huang, Yichen; Hu, Xinzhi; Wang, Penghui; Wu, Ronghua; Liu, Yan; Liu, Mei; Yang, Liu ·
Pre-transplant dual GLP-1 RA + SGLT2i therapy associated with improved post-transplant metabolic outcomes in solid organ transplant recipients.
Huang, Yu-Nan; Tsou, Min-Yu; Li, Pin-Hung; Chen, Jo-Ching; Liu, Yen-Liang; Meyerowitz-Katz, Gideon; Tsai, Tsung-Hsun; Su, Pen-Hua ·
Recombinant L. lactis secreting GLP-1 analogue: restored β-cell mass and insulin secretion, improved glucose tolerance, repaired gut barrier (tight junctions), and beneficially modulated gut microbiota in T2D mice.
Huang, Yuanjian; Lin, Xuancai; Deng, Min; Tang, Yanqing; Li, Simin; Xu, Binyan; Zeng, Weixing; Chen, Zerong; Hou, Xufeng; Lin, Ziqing; Meng, Xiaojing; Bai, Yang; Fan, Hongying; Zeng, Weisen ·
HLA-A*02:01-restricted PSMA and STEAP1 epitopes induced antigen-specific T cell responses in preclinical assessment, demonstrating immunogenicity for prostate cancer peptide vaccine development.
Huang, Yueting; Yang, Yang; Xie, Yanni; Shu, Yue; Yang, Siqi; Long, Xuezhi; Wen, Zhipeng; Duan, Xiaolu; Fu, Li; Gu, Di; Huang, Tuxiong ·
Scorpion venom neurotoxins targeting Na+, K+, Ca2+, and Cl- channels provide structurally diverse drug scaffolds for pain, epilepsy, cardiac arrhythmias, and autoimmune diseases (especially Kv1.3 blockers for autoimmunity).
Huang, Yun; Kamau, Peter Muiruri; Wang, Jiamin; Gao, Mingyue; Li, Bowen ·